InvestorsHub Logo

DR5

Followers 10
Posts 1100
Boards Moderated 0
Alias Born 01/05/2018

DR5

Re: rodman post# 13095

Tuesday, 03/05/2024 10:14:12 AM

Tuesday, March 05, 2024 10:14:12 AM

Post# of 13679
Good compilation of the product, Rodman. I went back and read the peer review from the Journal of Wound Care and their conclusion is definitive. Shareholders should be encouraged by this which I copied and am posting here:

“Conclusion
Taken together, the findings of this study showed that the NORC was more effective in controlling low to moderate bleeding that occurs during abdominal, thoracic, and vascular surgeries. The NORC was able to control bleeding within two minutes of application in all cases. Given the other characteristics of the NORC, such as a neutral pH, bacteriostatic and bioabsorbable properties, it should be considered for use as an adjuvant to control bleeding during open surgeries.”